Evaluation of Serum Interleukin‐6 Level as a Surrogate Marker of Synovial Inflammation and as a Factor of Structural Progression in Early Rheumatoid Arthritis: Results From a French National Multicenter Cohort
Authors:
Open Access
- 10 November 2014
- journal article
- research article
- Published by Wiley in Arthritis Care & Research
- Vol. 67 (7) , 905-912
Abstract
Objective: Interleukin‐6 (IL‐6) is a key cytokine in rheumatoid arthritis pathogenesis. We aimed to analyze the association between IL‐6 serum levels and joint inflammation at baseline and the correlation of time‐integrated IL‐6 values with structural damage during the first 36 months of early arthritis.Methods: IL‐6 was assessed by 2 different methods in 813 patients of the French early arthritis cohort ESPOIR (Etude et Suivi des Polyarthrites Indifférenciées Récentes) over 36 months. IL‐6 and C‐reactive protein (CRP) changes were correlated to radiographic progression assessed by the total Sharp/van der Heijde score (SHS). Synovium inflammation was assessed in a subgroup of 126 patients by ultrasonography (US). The relationship between SHS change and IL‐6 or CRP levels at baseline was investigated by a univariate regression and a multivariable analysis. A longitudinal model nested by visit and patient was conducted to assess the role of IL‐6 on SHS at each visit.Results: At baseline, IL‐6 was more strongly correlated with the swollen joint count than CRP level. In the univariate analysis, the time‐integrated value of IL‐6 was more strongly correlated with the swollen joint count and the variation of SHS than time‐integrated CRP level. Baseline IL‐6 was not independently associated with SHS change. Longitudinal models nested by patient showed that IL‐6 levels were associated with structural damage independently from the Disease Activity Score in 28 joints, smoking status, rheumatoid factor, and anti–citrullinated protein peptide antibody serology, treatments, and CRP levels.Conclusion: IL‐6 level was a marker of US synovitis at baseline. Repeated measurements of IL‐6 are associated with structural damage.Keywords
This publication has 44 references indexed in Scilit:
- EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritisAnnals of the Rheumatic Diseases, 2013
- Serum IL-6 and IL-21 are associated with markers of B cell activation and structural progression in early rheumatoid arthritis: results from the ESPOIR cohortAnnals of the Rheumatic Diseases, 2012
- Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destructionAnnals of the Rheumatic Diseases, 2012
- A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritisRheumatology, 2009
- The ESPOIR cohort: A ten-year follow-up of early arthritis in FranceJoint Bone Spine, 2007
- The HLA–DRB1 shared epitope alleles are primarily a risk factor for anti–cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritisArthritis & Rheumatism, 2006
- Plasma IL‐6, plasma VEGF, and serum YKL‐40: relationship with disease activity and radiographic progression in rheumatoid arthritis patients treated with infliximab and methotrexateScandinavian Journal of Rheumatology, 2006
- Comparison of synovial tissues from the knee joints and the small joints of rheumatoid arthritis patients: Implications for pathogenesis and evaluation of treatmentArthritis & Rheumatism, 2002
- The adrenal steroid status in relation to inflammatory cytokines (interleukin‐6 and tumour necrosis factor) in polymyalgia rheumaticaRheumatology, 2000
- INTERLEUKIN-6 (IL-6) INDUCES THE PROLIFERATION OF SYNOVIAL FIBROBLASTIC CELLS IN THE PRESENCE OF SOLUBLE IL-6 RECEPTORRheumatology, 1995